Y Intercept Hong Kong Ltd Increases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Y Intercept Hong Kong Ltd lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 193.1% during the third quarter, Holdings Channel reports. The institutional investor owned 19,151 shares of the biopharmaceutical company’s stock after acquiring an additional 12,617 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Ultragenyx Pharmaceutical were worth $1,064,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. True Wealth Design LLC purchased a new stake in Ultragenyx Pharmaceutical in the third quarter worth about $43,000. nVerses Capital LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $33,000. UMB Bank n.a. increased its position in Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 352 shares in the last quarter. Values First Advisors Inc. purchased a new position in Ultragenyx Pharmaceutical during the third quarter valued at $56,000. Finally, Capital Performance Advisors LLP bought a new stake in Ultragenyx Pharmaceutical in the third quarter worth $107,000. 97.67% of the stock is currently owned by institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. This trade represents a 7.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emil D. Kakkis sold 8,273 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total transaction of $413,650.00. Following the completion of the transaction, the chief executive officer now directly owns 2,195,712 shares of the company’s stock, valued at $109,785,600. This represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. TD Cowen increased their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. Royal Bank of Canada restated an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. cut their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.46.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $46.89 on Friday. The business’s 50-day moving average is $50.63 and its two-hundred day moving average is $49.05. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $37.02 and a fifty-two week high of $60.37. The company has a market cap of $4.33 billion, a price-to-earnings ratio of -7.25 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. During the same period in the previous year, the business posted ($2.23) earnings per share. The firm’s quarterly revenue was up 42.3% compared to the same quarter last year. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.